Welcome to our dedicated page for Corvus Pharmaceuticals news (Ticker: CRVS), a resource for investors and traders seeking the latest updates and insights on Corvus Pharmaceuticals stock.
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is a pioneering clinical-stage biopharmaceutical company focused on the development of novel immunotherapies to treat a broad spectrum of cancers and immune diseases. The company's core innovation is the selective inhibition of interleukin-2-inducible T cell kinase (ITK), which plays a crucial role in T cell and natural killer (NK) cell immune functions. Corvus' lead investigational product, soquelitinib (formerly CPI-818), has shown promise in optimizing T cell differentiation and enhancing immune responses against tumors, as well as in the management of autoimmune diseases.
Corvus is advancing soquelitinib through a Phase 3 registrational trial for relapsed peripheral T cell lymphoma (PTCL), an aggressive and typically treatment-resistant form of non-Hodgkin’s lymphoma. The company’s focus on ITK inhibition offers a new therapeutic approach, given the lack of FDA-approved treatments for relapsed PTCL. Soquelitinib has demonstrated the ability to prevent T cell exhaustion and promote the generation of cytotoxic killer T cells, critical in cancer therapy.
In addition, Corvus is investigating soquelitinib for other immune-mediated conditions, including atopic dermatitis. The company recently initiated a randomized, double-blind Phase 1 clinical trial to evaluate soquelitinib in patients with moderate to severe atopic dermatitis, aiming to provide an oral treatment alternative to current injectable biologics.
Other promising candidates in Corvus' pipeline include ciforadenant, an adenosine A2A receptor inhibitor that disables tumors' immune evasion mechanisms, and mupadolimab, a monoclonal antibody targeting CD73. These candidates are being studied for their efficacy in combination therapies for various cancers, including head and neck cancers and non-small cell lung cancer.
Financially, Corvus maintains a strong position, having raised significant capital through direct offerings to support its clinical trials and operational needs. With cash reserves projected to fund operations into late 2025, Corvus is well-positioned to achieve substantial milestones in its clinical programs. The company continues to foster critical partnerships, including collaborations with Angel Pharmaceuticals for the Chinese market.
Latest news highlights Corvus' progress in clinical trials and strategic financing moves, underscoring its commitment to bringing innovative immunotherapies to patients in need. For more information, visit the Corvus Pharmaceuticals website.
Corvus Pharmaceuticals (NASDAQ:CRVS) has announced the pricing of a public offering of 8,571,429 shares of common stock at $3.50 per share, totaling gross proceeds of $30 million. The offering will support the Phase 3 clinical trial of CPI-006 and the development of other product candidates. Additionally, underwriters have a 30-day option to purchase an extra 1,285,714 shares. The offering is set to close around February 17, 2021, pending customary closing conditions.
Corvus Pharmaceuticals (NASDAQ:CRVS) announced a public offering of its common stock, with all shares being sold by the company. Underwriters may purchase an additional 15% of the shares offered. The company plans to utilize the net proceeds for its Phase 3 clinical trial of CPI-006 and other product developments. The offering is subject to market conditions, and a registration statement for these securities was filed with the SEC.
Corvus Pharmaceuticals (NASDAQ: CRVS) has initiated a Phase 3 clinical trial for CPI-006, targeting hospitalized COVID-19 patients. This randomized, double-blind, placebo-controlled study aims to enroll around 1,000 participants globally, with results expected in Q4 2021. Preliminary Phase 1 results showed promising outcomes, with no patients progressing to mechanical ventilation and a median hospital discharge time of 3.5 days. CPI-006 aims to stimulate B cells for enhanced antibody production, potentially addressing SARS-CoV-2 variants. A separate Phase 2 trial is planned for CPI-818 in T-cell lymphoma.
Corvus Pharmaceuticals (NASDAQ: CRVS) reported new interim data on CPI-818 at the 62nd ASH Annual Meeting, showcasing its potential in treating T cell lymphomas and autoimmune lymphoproliferative syndrome (ALPS). The Phase 1/1b trial revealed promising anti-tumor activity, with significant tumor responses in advanced T cell malignancies. No severe treatment-related adverse events were recorded. Additionally, pre-clinical data indicated that CPI-818 could inhibit abnormal T cell activation in ALPS patients. The company plans to continue its studies and collaborate with Angel Pharmaceuticals in China.
Corvus Pharmaceuticals (CRVS) has announced new findings on its drug CPI-818 at the upcoming 62nd ASH Annual Meeting. The data includes results from a Phase 1/1b trial focused on T cell lymphoma and pre-clinical studies for treating autoimmune lymphoproliferative syndrome (ALPS). CPI-818 is an ITK inhibitor showing potential in blocking T cell activation in ALPS patients. Presentations will occur on December 5 and 6, 2020, highlighting CPI-818's efficacy and safety.
Corvus Pharmaceuticals (CRVS) announced the initiation of a pivotal Phase 2 randomized trial for CPI-006, aimed at treating COVID-19 in hospitalized patients. This trial is expected to start in December 2020, with results anticipated by mid-2021. The Phase 1 study demonstrated that CPI-006 activates a strong anti-SARS-CoV-2 antibody response and enhances patient recovery, with no reported drug-related toxicity. Key presentations highlighting the COVID-19 program will occur at the SITC Annual Meeting on November 13, 2020, showcasing CPI-006's immunotherapy potential.
Corvus Pharmaceuticals (NASDAQ: CRVS) announced the completion of patient enrollment in a Phase 1 study of CPI-006, an immunotherapy for hospitalized COVID-19 patients. Data presented at the SITC Annual Meeting indicates that CPI-006 enhances polyclonal humoral immunity, with patients showing significant antibody responses to SARS-CoV-2. Following promising results, a pivotal, randomized trial is set to begin in December 2020, with results anticipated by mid-2021. The R&D Symposium on November 12 will further detail these findings and updates on cancer programs.
Corvus Pharmaceuticals (NASDAQ: CRVS) will host a webcast R&D Symposium on November 12, 2020, focusing on its COVID-19 program and cancer updates. The event features key presentations, including an oral presentation of CPI-006 data at the SITC Annual Meeting from November 9-14, 2020. CPI-006 showed promise in stimulating immune response in mild to moderate COVID-19 patients. The symposium will discuss ongoing clinical trials and invite questions from attendees, providing insights into Corvus's innovative approaches in immunotherapy.
Corvus Pharmaceuticals (CRVS) reported a net loss of $9.8 million for Q3 2020, improving from $11.0 million in Q3 2019. Cash reserves decreased to $51.4 million from $78.0 million at year-end 2019. R&D expenses fell to $6.6 million, while G&A expenses rose to $3.2 million. Key developments include upcoming FDA meetings for ciforadenant in renal cell cancer and promising early results for CPI-006 in COVID-19, with plans for a larger trial by year-end. The co-founding of Angel Pharmaceuticals will enhance global pipeline development.
Corvus Pharmaceuticals (NASDAQ: CRVS) is set to present updated data from its Phase 1 study of CPI-006, an immunotherapy for COVID-19, at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting from November 9-14, 2020. A poster on the study will be available during the event, highlighting CPI-006's ability to stimulate anti-SARS-CoV-2 antibody responses.
The company will also host an R&D Symposium webcast on November 12, 2020, showcasing COVID-19 program data and advancements in its cancer portfolio.
FAQ
What is the current stock price of Corvus Pharmaceuticals (CRVS)?
What is the market cap of Corvus Pharmaceuticals (CRVS)?
What is Corvus Pharmaceuticals' lead product candidate?
What conditions is Corvus Pharmaceuticals targeting with soquelitinib?
What is the significance of ITK inhibition in Corvus Pharmaceuticals' research?
What other products are in Corvus Pharmaceuticals' pipeline?
What recent financial developments have supported Corvus Pharmaceuticals' research?
What is the background of Corvus Pharmaceuticals?
What partnerships does Corvus Pharmaceuticals have?
How is Corvus Pharmaceuticals addressing the unmet needs in relapsed PTCL?
How is soquelitinib being evaluated for atopic dermatitis?
What makes mupadolimab unique in Corvus Pharmaceuticals' research?
